TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01879176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Study: NCT02843646

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Walk Aide training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walk Aide training
Study: NCT02332213

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination

Intervention type: PROCEDURE
Intervention: Plasma/serum sampling
Description: Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Faecal sample acquisition
Description: Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis

Intervention type: PROCEDURE
Intervention: Histological evaluation of the surgery material
Description: The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)

Intervention type: PROCEDURE
Intervention: Histological evaluation of the surgery material
Description: The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
Study: NCT03684031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Control Training Program
Description: A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
Study: NCT02553278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VelaShape device
Description: Modified VelaShape radiofrequency device for non invasive fat reduction treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour I V3 device
Description: Contour I V3 device are non invasive for fat reduction.
Study: NCT01084382

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arthrospira platensis
Description: Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arthrospira platensis
Description: Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks.
Study: NCT01631526

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
Study: NCT03010982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat and [14C] Tazemetostat
Description: Tazemetostat is a selective oral small molecule inhibitor of EZH2.
Study: NCT02303314

Intervention type: DRUG
Group type: OTHER
Intervention: Trigonella Foenum-graecum Seed Extract

Intervention type: DRUG
Group type: OTHER
Intervention: Drug: Placebo
Study: NCT03313882

Intervention type: OTHER
Intervention: no intervention is involved

Intervention type: OTHER
Intervention: no intervention is involved

Intervention type: OTHER
Intervention: no intervention is involved
Study: NCT04914624

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ACBT training
Description: Performed 5 days before surgery and one month after surgery, twice a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acpella®PEP
Description: Continuously instruct patients to perform positive expiratory pressure training 5 days before surgery and one month after surgery, twice a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDP-type II external diaphragm pacemaker
Description: Use external diaphragm pacemaker to stimulate patients' diaphragms.
Study: NCT01183117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SM-01
Description: SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: balloon angioplasty
Study: NCT02740920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Study: NCT03794518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Plus dapaglifliozin
Description: Pioglitazone Plus dapaglifliozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (Beta blockers, ACEI, ARB, and aldosterone )
Study: NCT03177382

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total neoadjuvant treatment
Description: The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: The TME operation will be given after the end of the neoadjuvant treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: The TME operation will be given after the end of the neoadjuvant treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Patients will receive another 6 cycles of CAPOX after TME.
Study: NCT04698772

Intervention type: DRUG
Intervention: Ketamine
Description: Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)

Intervention type: DRUG
Intervention: Morphine
Description: Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
Study: NCT03100734

Intervention type: BIOLOGICAL
Intervention: Benepali
Description: As specified in the treatment arm

Intervention type: BIOLOGICAL
Intervention: Benepali
Description: As specified in the treatment arm

Intervention type: BIOLOGICAL
Intervention: Enbrel
Description: As specified in the treatment arm

Intervention type: BIOLOGICAL
Intervention: Enbrel
Description: As specified in the treatment arm
Study: NCT02790034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan low dose
Description: 2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan high dose
Description: 5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
Study: NCT04399642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroplasty
Description: All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Description: All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
Study: NCT03095898

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
Study: NCT01343095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foam Earplugs
Description: Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foam Earplugs
Description: Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noise Canceling Headphones
Description: Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
Study: NCT03662906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total.
Study: NCT03235479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg tablet QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet to match rimegepant dose QD
Study: NCT00856713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous dose of 2 mg NRL972
Study: NCT00346333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutein
Description: 12mg/d
Study: NCT00346333

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch control
Description: Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
Study: NCT01269749

Intervention type: RADIATION
Group type: OTHER
Intervention: RAI treatment
Description: Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).

Intervention type: DRUG
Group type: OTHER
Intervention: ATD Group
Description: Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
Study: NCT02846389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Exercise
Description: Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
Study: NCT03588702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF and PEMF treatment
Description: Treatment with Venus Legacy LB2 body applicator
Study: NCT02281045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVODIAL dialyzer and Selectbag citrate
Description: Evodial is a trademark of Hospal-Gambro.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regional citrate anticoagulation
Description: Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
Study: NCT03304366

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam (scheimpflug imaging)
Description: Corneal changes including thickness, elevations....etc
Study: NCT00741078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin, amlodipine
Study: NCT04360057

Intervention type: OTHER
Group type: OTHER
Intervention: PMD
Description: A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.

Intervention type: OTHER
Group type: OTHER
Intervention: PMDPlus
Description: A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
Study: NCT00485940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study: NCT01292681

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-modality imaging
Description: Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
Study: NCT00856713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous dose of 2 mg NRL972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous dose of 2 mg NRL972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous dose of 2 mg NRL972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous dose of 2 mg NRL972
Study: NCT03623464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile health application and Fitbit + standard of care
Description: Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Post-operative standard of care information
Study: NCT01659164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group treatment for adults with ADHD
Description: 14 weeks of group treatment for adults with ADHD
Study: NCT01487382

Intervention type: DRUG
Intervention: insulin aspart
Description: Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
Study: NCT02780427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).
Study: NCT03998436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: Galnobax-14% gel application along with Standard of Care

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Only Standard of Care
Description: Only Standard of Care treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle gel application along with Standard of Care
Study: NCT01731249

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch pollen allergen extract
Description: Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years